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Introduction 
Therapeutic application of antibiotics substantially improved life expectancy. Without 
antibiotics, humanity would not only loose its ability to treat bacterial infections, but also cancer 
therapies, transplantations and other immunosuppressive therapies, invasive surgeries and 
premature care would become impossible. One does not have to go far to face the tragic 
consequences of the shortage of antibiotics: in those countries that seriously lack resources, 
bacterial infections cause the second most deaths and are responsible for 60% of the pediatric 
deaths. Therefore, the public health hazard brought on by the spread of antibiotic resistance 
cannot be overemphasized. 
Despite the fact that antibiotic resistance has long been observed, our knowledge on the 
evolution of resistance and its collateral consequences is limited. The evolution of antibiotic 
resistance in the clinic is facilitated by mutations accumulating in the bacterial genome. The 
accumulation of these mutations could serve as a first step for the development of more 
specific resistance mechanisms providing clinically relevant resistance level. Additionally, these 
resistance mutations could affect bacteria’s susceptibility to other antibiotics as well. These 
collateral effects are referred to as evolutionary interactions. Cross-resistance or multidrug-
resistance occurs when resistance evolving to a given antibiotic causes increased resistance to 
one or more other antibiotics as well. Collateral sensitivity or hypersensitivity occurs in the 
exciting cases when resistance to a given antibiotic causes increased sensitivity to one or more 
other antibiotics. Collateral sensitivity was first described in a pioneering study 60 years ago. In 
this study, despite the then current laboratory conditions, the evolutionary interactions of 15 
antibiotics were systematically investigated. This experiment was primarily aimed at 
understanding the differences and similarities in the modes of action of antibiotics. 
Despite the obvious clinical relevance, apart from this pioneering phenomenological study 60 
years ago, no one investigated the evolutionary interactions of antibiotics until recently. This 
long hiatus of studies is surprising for two reasons: first, it has been known for long that 
antibiotic resistance has considerable fitness cost in antibiotic-free environment; and second, 
hypersensitivity, or in other words collateral sensitivity, has been expansively studied in cancer 
chemotherapy. Recent technological advances on the fields of laboratory automation and 
whole-genome sequencing have facilitated the systematic investigation of collateral sensitivity. 
Thanks to these advances, our first results on collateral sensitivity were published amongst 
other studies on this topic, and there are also several ongoing investigations on the possible 
clinical utilization of collateral sensitivity.  
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Aims 
 
During my work, our aim was to answer one of the most urgent questions of our days, namely 
to understand, what kind of genetic changes appear during the de novo evolution of antibiotic 
resistance and furthermore, how these genetic changes affect the susceptibility of bacteria 
towards other antibiotics. In order to systematically investigate these evolutionary interactions, 
we set up the following goals: 
 Investigation of the evolutionary forces driving the evolution of antibiotic resistance 
by a high-throughput laboratory evolution experiment, followed by whole-genome 
sequencing, on Escherichia coli bacteria. 
 
 Establishment of a high-throughput antibiotic susceptibility screening protocol to 
map the cross-resistance and collateral sensitivity interactions of 12 clinically 
relevant, conventional antibiotics that represent a diverse set of modes of action. 
  
 Investigation of the correlation between the physiological and evolutionary 
interactions of antibiotics. 
 
 Understanding the main patterns behind the cross-resistance interactions. 
 
 Uncovering the molecular mechanisms behind collateral sensitivity by the application 
of biochemical assays. Understanding how frequent collateral sensitivity is and how 
can we utilize it in the clinics. 
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Methods 
Laboratory evolutionary experiment. During the evolution we adapted parallel 
populations of Escherichia coli K12 BW25113 towards the gradually increasing concentration of 
one of 12 antibiotics, in batch cultures transferring 1% of the population into fresh medium 
every 24 hours. 96 parallel populations were started for each antibiotic and the evolution was 
continued until at least 10 parallel populations could grow or until we reached the solubility 
limit of an antibiotic. Depending on the growth and solubility limit, the evolution lasted 
approximately 240-384 generations. 
Whole genome sequencing. In order to identify the mutations behind the acquired 
resistance, the ancestor (Escherichia coli BW25113) and 63 adapted lines were next generation 
sequenced on SOLiD platform.  The whole genome sequencing and the analysis and validation of 
the acquired raw data was performed by the Sequencing Platform of the Biological Research 
Centre, under the direction of István Nagy, PhD. The raw results of the sequencing are available 
in the NCBI BioProject database (Accession: PRJNA248327 ID: 248327). 
Measuring the mutation rate. The mutation rate was measured by Luria-Delbrück 
fluctuation assay that is based on the frequency of the emergence of rifampicin resistance. The 
mutation rate was measured by my colleague, Orsolya Méhi, PhD.  
High-throughput antibiotic susceptibility screening. During the high-throughput 
screening we measured the susceptibility (cross-resistance and collateral sensitivity) of the 120 
parallel adapted lines towards those 11 antibiotics that they have not met before. For the 
measurement of these 1320 (120*11) data points we developed a high-throughput screening 
protocol followed by a robust statistical analysis. 
Measuring the relative fitness of the adapted lines. The relative fitness of the 120 
parallel adapted lines was measured during the antibiotic susceptibility screening by performing 
the screen on antibiotic-free medium as well. 
Calculating the chemical similarity. Chemical similarity was measured by the 
Tanimoto coefficient that captures the chemical fingerprint similarities of antibiotics. This 
analysis was performed by my colleague, Ádám Györkei. 
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Calculating the chemogenomic profiles. Chemogenomic profiles were based on the 
database of Girgis et al on the genes affecting susceptibility for each antibiotic. Chemogenomic 
profile similarity was calculated as the Jaccard coefficient for each pairs of antibiotics. The 
database of Girgis et al includes data for 9 of the 12 antibiotics applied by us. The 
chemogenomic profile similarities were calculated by my colleague, Viktória Lázár, Ph.D. 
Reinsertion of single mutations. In order to understand the molecular mechanisms 
behind the acquired resistance and evolutionary interactions, we chose 9 mutations that could 
play a key role in these mechanisms and reinserted each of these mutations separately into the 
wild type genetic background. Mutations were reinserted by a scarless-markerless method 
based on a suicide plasmid. The reinsertion was performed by my colleague, Csörgő Bálint, 
Ph.D. 
Measuring the bacterial membrane potential. In order to measure the effect of 
resistance to different antibiotics on the bacterial membrane potential, we randomly chose 2 
adapted lines for each antibiotic and measured their membrane potential by flow cytometer, 
applying the BacLight Bacterial Membrane Potential Kit.  
Hoechst accumulation measurement. In order to measure the membrane 
permeability of the adapted lines, we measured the intracellular accumulation of the Hoechst 
fluorescent dye (H33342 bisbenzimide) by a high-throughput, microplate-based protocol.  
Measuring the minimal inhibitory concentration (MIC) on dilution series. 
In most cases MIC was measured on standard linear dilution series in liquid medium. To 
maximize reproducibility and precision, the 11-step dilution series were prepared by a robotized 
liquid handling system. 
Measuring the minimal inhibitory concentration (MIC) by E-test strips. 
Inoculum preparation and plating on agar, as well as the placing of the E-test strips and reading 
of MIC values were performed according to the manufacturer’s instructions. 
Effect of AcrAB efflux pump overexpression and deletion on susceptibility. 
In order to understand the role of the AcrAB efflux system in the observed evolutionary 
interactions, we modified 3 different strains as follows: we either deleted the acrB gene by P1 
transduction, or we transformed a multicopy plasmid (pUCacrAB) encoding the AcrAB efflux 
pump into these 3 strains. The pUCacrAB plasmid was kindly provided by Kunihiko Nishino, 
Ph.D. and Akihito Yamaguchi, Ph.D. (Osaka University, Osaka, Japan).  
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Results 
I) High-throughput laboratory evolution to establish lines with high 
resistance towards one of 12 antibiotics. The evolution was initiated from a 
common ancestor (Escherichia coli BW25113) towards the gradually increasing concentrations 
of one of 12 antibiotics, with 96 parallel populations per antibiotic in batch culture. Under this 
strict gradual increasing the experiment was continued until at least 10 parallel populations 
were growing for the antibiotic or the concentration reached the solubility limit of the given 
antibiotic. In the end the evolution lasted for around 240-384 generations and despite the short 
timeframe, bacteria could even grow at as high concentrations as 328-fold over the minimal 
inhibitory concentration (MIC) of the applied antibiotic. 
II) Adaptive mutations dominated in the laboratory evolved antibiotic-
resistant lines. Several results suggest that mutations identified in protein coding regions 
were driven by the selective pressure of the antibiotic. First, 87% of the point mutations were 
non-synonymous, causing amino acid susbtitution. Second, we identified several mutations that 
are identical to those identified in environmental or clinical resistant isolates not only on the 
level of amino acid susbstitution, but also in the exact nucleic acid substitution. This second 
result is also extremely important from another aspect: it shows that laboratory evolution can 
predict some of the genomic resistance mutations that appear in the clinic. 
III) Loss of function mutations are prevalent. 27% of the observed point mutations, 
small deletions and insertions (between 1-100 basepairs) generated early, in-frame stop codons, 
frameshifts or the disruption of the start codon. These mutations most probably lead to the 
production of inactive proteins or proteins with compromised activities. In several cases, these 
loss of function mutations provide resistance to multiple antibiotics, like in the case of loss of 
function mutations of the transcriptional repressores of the antibiotic stress-response (for 
example the acrR, marR, mprA). These mutations alone could provide multidrog resistance. 
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IV) Evidences of parallel evolution. Signs of parallel evolution were present on both 
the level of affected functional modules, genes, amino acids and even nucleotides. First, 35% of 
the affected genes acquired mutations in at least 2 independent, parallel adapted lines. 
Moreover, 8% of the identified point mutations appeared in at least 2 independent, parallel 
adapted lines. Remarkably, 66% of those genes that acquired mutations in independent lines 
acquired mutations in lines adapted to different antibiotics. This result suggests that despite the 
different mechanisms of action of various antibiotics, the key elements of the development of 
resistance are provided by overlapping functional modules. 
V) High-throughput screening of the antibiotic susceptibilities of the 
adapted lines. The high-throughput protocol was validated by 2 independent control 
experiments. First, while optimizing the protocol colony sizes were measured on agar plates in 
parallel. Second, results for cross-resistance were validated by measuring the minimal inhibitory 
concentrations (MIC) with standard E-test stripes for a subset of the adapted lines. Based on 
this MIC measurement the false positive rate was found to be 5%, while the false negative rate 
was found to be 16%. 
VI) Treatment with a single antibiotic can lead to multidrug resistance. The 
evolution of multidrug resistance was frequent despite applying the antibiotics alone in 
monotherapy: 52% of the investigated antibiotic pairs showed cross-resistance interaction in at 
least one direction. The strength of cross-resistance was very diverse, from as mild as 2-fold 
increase in the minimal inhibitory concentration (MIC) to as high as 128-fold increase in the 
MIC. Strong cross-resistance interactions were not limited to antibiotics with similar modes of 
action or belonging to the same antibiotic class. 
VII) Parallel evolution is partially responsible for the observed cross-
resistance interactions. Despite the fact that the 12 applied antibiotics cover a wide 
range of mode of action, we found signs of parallel evolution even between distinct antibiotic 
classes. While analysing the mutation profile similarity of the independent adapted lines, we 
found that those antibiotic pairs for which there was only slight similarity in the mutation profile 
of the adapted lines exhibited fewer cross-resistance interactions than those antibiotic pairs 
where the mutation profile was highly similar. We further demonstrated the role of individual 
mutations in the cross-resistance interactions by reinserting 9 of the identified mutations 
individually into the wild-type genetic background and measuring their effect on susceptibility 
towards the 12 antibiotics applied. 
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VIII) The effect of antibiotic properties on cross-resistance interactions. 
The chemical structure similarity (measured in the Tanimoto coefficient that prepares a 
chemical fingerprint for each antibiotic based on the presence and absence of specific structural 
motifs and then compares these motifs) showed almost no correlation with the cross-resistance 
interactions. Correlation between the similarity of mode of action and cross-resistance was 
tested by comparing the mutation profile similarity and the chemogenomic profile similarity of 
each antibiotic pair. In this case we found that those antibiotic pairs that showed high overlap in 
their chemogenomic profile similarity also led to the acquisition of a similar set of mutations in 
the laboratory evolution. Thus we can conclude that although the chemical structure has no 
effect on the cross-resistance interaction, the chemogenomic profile similarity significantly 
influences the appearance of these interactions. 
IX) Collateral sensitivity: the Achilles’ heel of multidrug-resistant bacteria. 
Collateral sensitivity interactions are surprisingly frequent: 35% of all investigated antibiotic 
pairs showed collateral sensitivity in at least one direction. Most of these collateral sensitivity 
interactions appeared between antibiotic pairs that show negligible overlap in their 
chemogenomic profiles. Accordingly, collateral sensitivity is more likely to appear between 
antibiotics that have distinct modes of action. The observed collateral sensitivity network was 
dominated by aminoglycosides: 44% of all collateral sensitivity interactions were observed 
between an aminoglycoside and a non-aminoglycoside. The strength of collateral sensitivity was 
usually around a 2-10-fold decrease in the minimum inhibitory concentration (MIC). This 
decrease is proportional to the 2-8-fold increase in MIC provided by multidrug efflux pump 
mutations. 
X) Multiple mechanisms behind aminoglycoside resistance. The complexity of 
aminoglycoside resistance is at first suggested by the number of mutations: aminoglycoside-
adapted lines acquired an average of 11.4 mutations per line, while non-aminoglycoside 
adapted lines acquired only an average of 5.65 mutations per line. A pathway enrichment 
analysis revealed that one of the main targets of selection in case of the aminoglycosides was 
the translation machinery, in agreement with their mode of action. Moreover, mutations were 
also enriched in genes that play roles membrane transport processes, phospholipid biosynthesis 
and the maintenance of cell envelope homeostasis. The biosynthesis pathway of polyamines, 
that can bind intracellular reactive oxygen species, was also affected. Another large group of 
mutated genes were those genes that can directly or indirectly influence the membrane 
potential of the bacteria. 
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XI) Opposing effects of aminoglycoside-resistance mutations on membrane 
potential. We hypothesized that those mutations in the aminoglycoside-adapted lines that 
have an effect on the membrane potential of the bacteria play a key role in the development of 
collateral sensitivity. Our hypothesis is based on two key observations from the literature: first, 
aminoglycosides uniquely require proton motive force for their bacterial uptake; second, several 
non-aminoglycoside antibiotics are eliminated by proton motive force dependent multidrug 
efflux pumps from the bacteria. Based on these two observations we thought that in order to 
rapidly acquire an initial small resistance to aminoglycosides, Escherichia coli drastically 
decreases its membrane potential. However, these mutations diminish the activity of the major 
proton motive force dependent multidrug efflux pumps. Indeed, many of the observed 
mutations in aminoglycoside-adapted lines directly or indirectly influence the membrane 
potential. On top of these mutations we also performed to biochemical assays to prove our 
hypothesis. First, we used DiOC2(3) fluorescent dye to demonstrate that the membrane 
potential is actually significantly lower in aminoglycoside-adapted lines. Second, we also 
detected increased intracellular Hoechst dye accumulation in these aminoglycoside-adapted 
lines, that suggests decreased activity of the major efflux pumps. 
XII) A single mutation in the gene trkH leads to widespread collateral 
sensitivity. TrkH supports the bacterial membrane potential by the uptake of potassium 
ions. TrkH acquired mutations in 64% of the aminoglycoside-adapted lines. Reinsertion of one of 
these mutations, that lies close to the ion channel, into the wild-type genetic background could 
alone provide resistance to aminoglycosides and collateral sensitivity to many other antibiotics. 
The trkH* single mutant strain also exhibited lower membrane potential and increased Hoechst 
accumulation. These findings further supported our hypothesis that this collateral sensitivity is 
caused by a significant decrease in the proton motive force. 
XIII) Collateral sensitivity is partly related to the AcrAB efflux system. The 
AcrAB multidrug efflux pump works on a proton motive force dependent way, therefore, we 
assumed that this efflux system plays a key role in the collateral sensitivity pattern observed by 
us. To investigate the role of AcrAB pump in collateral sensitivity, we transformed the trkH* 
single mutant strain and an aminoglycoside-adapted line with a multicopy plasmid encoding the 
Escherichia coli AcrAB efflux pump and its native promoters. The sensitivity of these 
transformed strains was tested towards four antibiotics that are all known substrates of the 
AcrAB efflux pump. The AcrAB overexpressing plasmid provided significant resistance towards 
all tested antibiotics in the wild-type background, however, the same plasmid had very little 
effect in the trkH* strain and the aminoglycoside-adapted line.   
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